Forma Therapeutics, Inc.

Clinical trials sponsored by Forma Therapeutics, Inc., explained in plain language.

Now part of Novo Nordisk A/S NVO NYSE

A biopharmaceutical company developing therapies for rare diseases and cancer, acquired by Novo Nordisk.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New pill could shield kids with sickle cell from stroke Results expected Aug 2027 (estimated) May already have reported ↗

Browse trials soon ready across all sponsors →

Trials to join now! 2 Not yet finished but already full! 1 Completed 2 Terminated 2

New pill could slash sickle cell pain crises

Disease control Ongoing

This large Phase 3 trial is testing an oral drug called etavopivat in 450 people with sickle cell disease. The goal is to see if taking a pill once daily can raise hemoglobin levels and reduce the number of painful vaso-occlusive crises compared to a placebo. Participants must ha…

Phase 3 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:04 UTC

Forma Therapeutics, Inc.

Upcoming readouts

New pill could slash sickle cell pain crises